CHIs may reduce the COVID-19 severity by reducing the SARS-CoV-2 entry points at ACE2/DPP4/CD147 axis in the initial phase and immunomodulation in the late phase of the disease by suppressingTLR4/NF-kB signaling pathway. Here, ACE2 is linked to COVID-19.